BRENTUXİMAB+ NIVOLUMAB

Kaynaklar:

1- Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183-1194.

2- Diefenbach CS, Hong F, Ambinder RF, et al. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial. Lancet Haematol. 2020;7(9):e660-e670.

3- Stamatoullas A, Ghesquieres H, Filliatre LC, et al. Brentuximab vedotin in first refractory/relapsed classical Hodgkin lymphoma patients treated by chemotherapy (ICE) before autologous transplantation. Final analysis of phase II study [abstract]. Blood. 2019;134(suppl 1). Abstract 132.

4- Ranjana H Advani, Alison J Moskowitz, Nancy L Bartlett, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results.  Blood. 2021 Aug 12;138(6):427-438.